Scroll down
TAVR with the Edwards SAPIEN 3 valve
Better Than Surgery
for Intermediate-Risk Patients*
*The PARTNER II trial intermediate-risk cohort, VI population (n=2,005); the difference in the primary endpoint (composite of all-cause mortality, all stroke, and ≥ moderate aortic regurgitation at one year) event rate between TAVR with the SAPIEN 3 valve and surgery appeared to be clinically significant.

Ask your doctor about transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve today.

Our Latest Valve

Low frame height

Made from cobalt chromium, for its radial strength and durability

Proven valve tissue

Utilizes the same bovine pericardial tissue (from a cow's heart) as Edwards surgical valves

Outer sealing skirt

Virtually eliminates moderate to severe leakage around the valve*

*PARTNER II trial high-risk TF SAPIEN 3 valve cohort 30-day results

Approved for intermediate-risk patients

The SAPIEN 3 valve builds upon research and development we have conducted over several decades.

As the leader in heart valve science and innovation, we have purposefully designed our transcatheter heart valves with the same proven materials and features as our leading surgical valves.


The Clinical Difference

Transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 valve demonstrated 75% lower rates of 30-day all-cause mortality and disabling stroke compared to surgery in intermediate-risk patients.

  • †The PARTNER II trial intermediate-risk cohort 30-day unadjusted clinical event rates for TAVR with the SAPIEN 3 valve, as treated population (n=1,077).
  • ‡The PARTNER II trial intermediate-risk cohort unadjusted clinical event rates, AT population.
Your Procedure
At this moment, thousands of our heart valves are
Helping people live their lives
Around the world, TAVR has helped people suffering from severe aortic stenosis. If you are researching treatment options for severe aortic stenosis or will be having the TAVR procedure, we are here to help you.

Benefits of TAVR:

  • Relief of symptoms, in some cases immediately
  • Reduction in pain and anxiety
  • Improved heart function
  • May shorten recovery time to resume everyday activities

Quality of Life Improvement:

TAVR has shown improvement in a patient's health as early as 30 days after their procedure. Patients reported improvements in quality of life, including:

  • Ability to take care of themselves
  • Ability to participate in everyday activities

The most serious RISKS of the TAVR procedure are:
death, major stroke, major vascular complications, and life threatening bleeding event.*

It is important to talk with your doctor about the exact procedure you will have, the product you will receive, and the literature on clinical studies using that product.

*See the Edwards SAPIEN 3 valve patient brochure for more detailed information on these and other risks.

Transfemoral Approach

The most common way to perform TAVR is through the transfemoral approach. An incision will be made in your leg, where your doctor will insert a short, hollow tube called a sheath.

The Edwards SAPIEN 3 transcatheter heart valve will be placed on the delivery system and compressed on a balloon. The delivery system carrying the valve will be placed through the sheath and delivered to your aortic valve. The balloon of the delivery system will be inflated, expanding the new valve within your diseased valve.

The valve will push the leaflets of your diseased valve aside, securing itself into place. The new valve should begin working immediately.

TAVR is a less invasive procedure available for people who need their aortic valve replaced and are at intermediate or greater risk for open heart surgery.

To find out if TAVR is right for you, please talk with your doctor and locate a TAVR Center near you.

Your Guide

This guide will help you ask the right questions during your next doctor's visit.

Order Info Kit

These educational materials will help you learn more about severe aortic stenosis and TAVR.

Our Journey
Started more than 50 years ago
AND CONTINUES TODAY
Our trusted expertise in valve innovation
has helped over
1 million patients in critical need
1958
2016

Click on the arrow to view our valve history

Swipe >>

It started with a dream ...
1958
Miles Edwards
Edwards Lifesciences was started by Miles "Lowell" Edwards, who had a dream to create the first artificial heart. He decided to first focus on heart valves due to a large unmet need in this area.
1960
Starr-Edwards Mechanical Valve
Edwards introduced the world's first successful mechanical heart valve. The Starr-Edwards valve began the modern era of surgery to treat advanced heart valve disease.
1976
Carpentier-Edwards Porcine Valve
One of the first tissue valves available worldwide, created from a pig's (porcine) aortic valve. Tissue valves were created to help eliminate the need to take medicine that helps prevent the blood from clotting, which is typically needed for mechanical valves.
1981
Carpentier-Edwards Perimount Pericardial Aortic Valve*
The first bioengineered aortic tissue valve created in the world. It was made with bovine pericardial tissue (the sac around a cow's heart) and was engineered for clinical performance.

*First clinical use

2007
Edwards Sapien Transcatheter Heart Valve*
One of the very first transcatheter aortic valves for patients who are high risk or too sick to undergo open heart surgery. This transcatheter valve replacement era represents a major achievement in the treatment of patients with severe aortic stenosis.

*CE mark approval in Europe 2007

2014
Edwards Sapien XT Transcatheter Heart Valve
Introduced with a newly designed frame that can be delivered into a smaller anatomy, the Edwards SAPIEN XT valve is offered in more sizes than ever before, expanding the number of patients who can be treated with this less invasive option.
and the dream continues ...
Today
Edwards Sapien 3 Transcatheter Heart Valve
The latest advancement in transcatheter aortic valve replacement from Edwards builds on our expertise and history in valve innovation and our proven balloon-expandable technology. The unique, transformational design of the SAPIEN 3 valve continues to drive consistent, landmark outcomes across the globe, and is approved for patients at intermediate or greater risk for open heart surgery.
Edwards SAPIEN valves are
The most widely used
transcatheter heart valves in the world
More than
150,000
Patients
treated with Edwards SAPIEN
transcatheter heart valves
Worldwide*
*Includes all valves from the Edwards SAPIEN transcatheter heart valve platform.
Treating
Patients
in over 65
Countries
around the world
Transcatheter
Aortic Valve
approved in the U.S. in 2011

When we design a heart valve...
we see the potential for a BETTER LIFE.

We see YOU.